Loading...
XNASABUS
Market cap608mUSD
Dec 27, Last price  
3.21USD
1D
0.63%
1Q
-16.19%
Jan 2017
31.02%
IPO
-54.40%
Name

Arbutus Biopharma Corp

Chart & Performance

D1W1MN
XNAS:ABUS chart
P/E
—
P/S
33.53
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
24.58%
Rev. gr., 5y
25.19%
Revenues
18m
-53.51%
12,169,61913,291,04113,604,33115,923,3499,639,75013,779,40521,351,32216,304,54714,180,79215,464,15015,000,00024,873,0001,500,00010,700,0005,900,0006,011,0006,914,00010,988,00039,019,00018,141,000
Net income
-73m
L+4.89%
0018,080,5270000029,947,878-14,064,226-38,800,000-61,121,000-384,100,000-84,400,000-57,100,000-153,723,000-65,211,000-77,351,000-69,456,000-72,849,000
CFO
-86m
L+143.06%
0000000033,270,564-6,738,559-12,421,000-54,785,000-57,885,000-48,600,000-67,900,000-71,006,000-51,441,000-67,532,000-35,356,000-85,936,000
Earnings
Feb 26, 2025

Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc.; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd.; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB-729 for the treatment of chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
URL
https://www.arbutusbio.com/
IPO date
Nov 13, 2010
Employees
96
Domiciled in
US
Incorporated in
CA

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
18,141
-53.51%
39,019
255.11%
10,988
58.92%
Cost of revenue
169,875
103,669
84,391
Unusual Expense (Income)
NOPBT
(151,734)
(64,650)
(73,403)
NOPBT Margin
Operating Taxes
4,444
1,104
Tax Rate
NOPAT
(151,734)
(69,094)
(74,507)
Net income
(72,849)
4.89%
(69,456)
-10.21%
(77,351)
18.62%
Dividends
(12,139)
Dividend yield
2.94%
Proceeds from repurchase of equity
29,852
42,787
134,665
BB yield
-7.19%
-12.17%
-32.58%
Debt
Debt current
850
372
383
Long-term debt
10,064
4,002
4,845
Deferred revenue
5,999
Other long-term liabilities
7,600
17,896
21,594
Net debt
(121,373)
(179,902)
(185,777)
Cash flow
Cash from operating activities
(85,936)
(35,356)
(67,532)
CAPEX
(1,008)
(512)
(809)
Cash from investing activities
50,773
(74,942)
(12,678)
Cash from financing activities
30,647
31,814
137,236
FCF
(151,010)
(67,833)
(73,250)
Balance
Cash
126,003
146,913
155,317
Long term investments
6,284
37,363
35,688
Excess cash
131,380
182,325
190,456
Stockholders' equity
24,748
64,446
103,954
Invested Capital
94,742
98,488
89,693
ROIC
ROCE
EV
Common stock shares outstanding
165,960
150,939
106,242
Price
2.50
7.30%
2.33
-40.10%
3.89
9.58%
Market cap
414,901
17.97%
351,689
-14.90%
413,283
53.51%
EV
293,528
171,787
227,506
EBITDA
(150,330)
(63,223)
(71,650)
EV/EBITDA
Interest
459
1,726
2,857
Interest/NOPBT